Overview

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

Status:
Not yet recruiting

Trial end date:
2026-10-16

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine the tolerability of erdafitinib intravesical delivery system (TAR-210) in Japanese participants.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.